Phase 1 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with painful sciatica (nerve pain that shoots down the leg to or below the knee) and have not had enough relief from standard treatments.
- People with a body mass index (a measure of body weight relative to height) below 35.
Who may not be able to join:
- People who have a significant medical condition or another source of pain that could affect how results are measured.
- People who currently need blood or platelet transfusions for any reason.
- People who have been diagnosed with schizophrenia, bipolar disorder, or major depressive disorder.
- People who have a higher-than-normal risk of bleeding, or who are taking blood-thinning medications or medicines that affect how platelets work.
- People who have a history of, or currently have, nerve damage related to diabetes, problems with the automatic functions of the nervous system, or other conditions affecting the peripheral nerves.
- People who have had a heart attack in the past 6 months, or who have been diagnosed with heart failure.
- People who have an active cancer or tumour.
- People who have previously had surgery for back pain.
- People who have recently used medications that suppress the immune system, or steroid medications taken by mouth or through a drip.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Consano Chief Medical Officer, Consano Bio
Phone: AUS: +61 (1800) 057510
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Incidence and severity of treatment emergent adverse events (TEAEs); Incidence and severity of adverse events of special interest (AESIs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.